UBS Group
FMTX

UBS Group’s Forma Therapeutics Holdings, Inc. Common Stock FMTX Stock Holding History

UBS Group’s Portfolio FMTX Stock Details FMTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-222,712
Closed -$4.44M – 11967
2022
Q3 		$4.44M Buy
222,712
+179,496
+415% +$2.37M ﹤0.01% 2475
2022
Q2 		$298K Sell
43,216
-71,909
-62% -$505K ﹤0.01% 4627
2022
Q1 		$1.07M Buy
115,125
+40,591
+54% +$432K ﹤0.01% 4030
2021
Q4 		$1.06M Buy
74,534
+52,754
+242% +$913K ﹤0.01% 4339
2021
Q3 		$505K Buy
21,780
+13,825
+174% +$327K ﹤0.01% 4728
2021
Q2 		$198K Sell
7,955
-41,886
-84% -$1.13M ﹤0.01% 5356
2021
Q1 		$1.4M Buy
49,841
+48,066
+2,708% +$1.73M ﹤0.01% 3908
2020
Q4 		$62K Buy
1,775
+1,508
+565% +$65.7K ﹤0.01% 6005
2020
Q3 		$13K Sell
267
-170
-39% -$6.87K ﹤0.01% 6666
2020
Q2 		$20K Buy
+437
New +$18.9K ﹤0.01% 6575

UBS Group's FMTX Position: Q4 2022 in Review

UBS Group sold out of Forma Therapeutics Holdings, Inc. Common Stock (FMTX) in Q4 2022, closing a stake of 222,712 shares — an estimated $4.44M sold.

UBS Group first reported a position in FMTX in Q2 2020 and held it in 10 quarters. The position peaked at $4.44M in Q3 2022. 0 funds tracked by Wall St. Rank hold FMTX as of Q4 2022.

  • UBS Group reported no remaining Forma Therapeutics Holdings, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • UBS Group sold 222,712 Forma Therapeutics Holdings, Inc. Common Stock shares in Q4 2022, an estimated $4.44M.
  • UBS Group first reported a position in Forma Therapeutics Holdings, Inc. Common Stock in Q2 2020 and held it in 10 quarters.
  • UBS Group's Forma Therapeutics Holdings, Inc. Common Stock position peaked at $4.44M in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Forma Therapeutics Holdings, Inc. Common Stock as of Q4 2022.

Based on UBS Group's 13F filing for Q4 2022, filed 8 Feb 2023.